TIDMUPR
RNS Number : 4624Z
Uniphar PLC
18 September 2020
Board Changes
Highly Experienced Global Healthcare Executive to Join Uniphar
Board
Dublin, London | 18 September 2020
Uniphar plc (the "Company") is pleased to announce the
appointment of Jeffrey ("Jeff") Berkowitz to its Board as an
independent non-executive Director with immediate effect.
Mr. Berkowitz has extensive global healthcare experience, having
held senior executive positions across most key business areas in
the global healthcare supply chain at UnitedHealth Group/Optum,
Walgreens Boots Alliance Inc. and Merck & Co Inc.
He has been recognised three times in PharmaVoice magazine as
one of the 100 Most Inspiring Leaders in the Life Sciences in the
past decade and was the recipient of PharmaVoice's inaugural Red
Jacket Award.
Jeff Berkowitz is CEO of Real Endpoints LLC, a leader in
insights, supports and tools to strengthen access to pharmaceutical
innovation for an evolving healthcare landscape with specific focus
on value-based arrangements, patient services and access support
for pharma manufacturers and payors.
Mr. Berkowitz also serves on the board of directors of H.
Lundbeck A/S, Esperion Therapeutics, Inc., and Zealand
Pharmaceuticals, Inc. He is an Editorial Advisor to Life Science
Leader and Pharmaceutical Commerce magazines and has previously
served on the Board of Directors of the Swiss-American Chamber of
Commerce.
Mr. Berkowitz's wide-ranging healthcare expertise, coupled with
his executive and board experience across multiple publicly quoted
companies, brings a depth of expertise to the Uniphar board and is
an important step in the Company's board transition strategy as
outlined at IPO.
Other Board Developments
The Company also announces that Heather Ann McSharry is stepping
down from the Board with immediate effect.
The Company also announces the following non-executive director
changes to the Committees of the Board with immediate effect:
-- Sue Webb, Independent Non-Executive Director, has been appointed to the Audit Committee.
-- Jeff Berkowitz and Paul Hogan, Independent Non-Executive
Director, have been appointed to the Nominations Committee, with
Jeff Berkowitz also appointed as Chair of the Nominations
Committee; and
-- Paul Hogan is also assuming the role of Senior Independent Director.
The updated composition of the Committees of the Board will be
available on the Company's website: www.uniphar.com .
Maurice Pratt, Chairman of Uniphar plc, commented:
"We are delighted to attract a candidate of Jeff Berkowitz's
experience and stature to the Uniphar Board. With over 25 years'
service in a variety of senior level roles in global healthcare
businesses, Jeff will add significantly to the depth and breadth of
industry insights available to the Board and the senior team in
line with our international growth strategy. On behalf of all our
Directors, I would like to take this opportunity to warmly welcome
Jeff to the Board of Uniphar."
"I would also like to thank Heather Ann for the valuable
contribution she has made to Uniphar since joining the Board.
Heather Ann's experience and expertise were a great support in
executing the successful IPO of Uniphar in 2019 and transitioning
Uniphar to operating as a public company, and we wish her well for
the future."
Additional Information:
Jeff Berkowitz (a US citizen, aged 54 years) does not hold any
ordinary shares or share options in the Company.
Prior to Real Endpoints, Mr. Berkowitz served as an Executive
Vice President of UnitedHealth Group/Optum, where he led Optum's
International division as CEO while also driving key strategic
initiatives within its pharmacy benefits management division,
OptumRx.
Before this, he was a member of the Executive Committee of the
Walgreens Boots Alliance, Inc. ("Walgreens"), where he served as
President of Pharma and Global Market Access. Jeff was responsible
for generic and branded procurement, inventory management,
relationships with pharmaceutical companies as well as the
companies pricing and reimbursement strategies. He also led
Walgreens specialty pharmacy business with over $10 billion in
revenue and 5,800 employees.
Before joining Walgreens in 2010, Mr. Berkowitz was Senior Vice
President of Global Market Access for Merck & Company, Inc.
Mr. Berkowitz had held a similar position at Schering-Plough,
where he started as legal director for Schering-Plough's managed
care and commercial group in 1998.
Before joining Schering, Mr. Berkowitz was a healthcare attorney
for the international law firm Proskauer LLP in New York and
Washington, D.C.
Mr. Berkowitz earned his bachelor's degree in political science
from Union College in Schenectady, N.Y., and his Juris Doctor from
Brooklyn Law School in Brooklyn, N.Y.
Current Directorships / Partnerships Former Directorships/Partnerships
Lundbeck A/S Infinity Pharmaceuticals,
Inc.
Esperion Therapeutics, Inc. Swiss American Chamber of
Commerce
Zealand Pharmaceuticals A/S
Life Science Leader and Pharmaceutical
Commerce Magazines (Editorial Advisory
Board)
Project Explorer, LTD
The Company confirms that there is no other information that is
required to be disclosed in accordance with Rule 17 of the AIM
Rules for Companies and Rule 5.22 (b) of Chapter 5: Additional
Rules for the Euronext Growth Market operated by Euronext
Dublin.
--- ENDS ---
Contact details
Uniphar Group Tel: +353 (0) 1 428 7777
Tim Dolphin, Chief Financial Officer
Brian O'Shaughnessy, Group Director of Corporate Development
Q4 PR Tel: +353 (0) 1 475 1444 or +353 (0)
87 235 6461
Iarla Mongey, Public Relations Advisor to Uniphar Group
Davy (Nomad and Euronext Growth Advisor) Tel: +353 (0) 1 679 6363
Fergal Meegan
Barry Murphy
Tom Tynan
About Uniphar Group
Headquartered in Dublin, Ireland, Uniphar plc is an
international diversified healthcare services business, servicing
the requirements of more than 200 multinational pharmaceutical and
medical technology manufacturers across three divisions -
Commercial & Clinical, Product Access and Supply Chain &
Retail.
The Group has strong established relationships with 7 of the top
10 pharma companies and 6 of the top 10 medical device companies.
With a workforce of more than 2,300, the Group is active in
Ireland, the UK, the Benelux, the Nordics and the US, delivering
unlicensed and specialty medicine on a global basis.
The Group's vision is to improve patient access to
pharmaco-medical products and treatments by enhancing connectivity
between manufacturers and healthcare stakeholders. Uniphar
represents a strong combination of scale, growth and
profitability.
Commercial & Clinical
In Commercial & Clinical the Group provides sales, marketing
& distribution solutions to multinational pharmaceutical and
medical device manufacturers on an outsourced basis. Active in
Ireland, the UK, the Benelux, and the Nordics, the Group is growing
with its clients to provide pan-European solutions. Uniphar has
built a fully integrated multi-channel solution that is supported
by highly experienced, clinically trained teams to deliver
exceptional outcomes for all clients.
Product Access
In Product Access the Group is growing two distinct service
offerings: 1) "On Demand Access", which are pharmacy led solutions
for sourcing and supplying unlicensed medicines to meet the needs
of both retail and hospital pharmacists; and 2) "Exclusive Access",
which are manufacturer led solutions for controlling the release of
speciality medicines for specifically approved patient populations
in agreed markets. The Group currently delivers product access
solutions on a global basis.
Supply Chain & Retail
Uniphar is an established market leader in Ireland with c.50%
market share in the wholesale/hospital market, supported by a
network of c.300 owned, franchised and symbol group pharmacies. The
business supports the diverse customer base through the provision
of strong service levels coupled with innovative commercial
initiatives. Supply Chain & Retail is an Irish only business
for the Group, although the manufacturer relationships and
infrastructure are utilised for the benefit of the growth
divisions, Commercial & Clinical and Product Access.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAEAENPFSPEEFA
(END) Dow Jones Newswires
September 18, 2020 07:00 ET (11:00 GMT)
Uniphar (LSE:UPR)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Uniphar (LSE:UPR)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024